Form 8-K

8-K — ANAVEX LIFE SCIENCES CORP.

Accession: 0001731122-26-001294

Filed: 2026-09-28

Period: 2026-09-24

CIK: 0001314052

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Changes in Control of Registrant

Item: Submission of Matters to a Vote of Security Holders

Documents

8-K — e7977_8-k.htm (Primary)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: e7977_8-k.htm · Sequence: 1

false

0001314052

2026-09-24

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September

24, 2026

ANAVEX

LIFE SCIENCES CORP.

(Exact name of registrant as specified in its charter)

Nevada

001-37606

98-0608404

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

630 5th Avenue, 20th Floor, New York, NY USA 10111

(Address of principal executive offices) (Zip Code)

1-844-689-3939

Registrant’s telephone number, including area

code

Check the appropriate box below if the Form 8-K filing

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction

A.2. below):

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of

the Act:

Title of Each Class

Trading symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.001 per share

AVXL

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an

emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark

if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.01 Changes in Control of Registrant.

As further described under Item 5.07 of this Current Report on Form 8-K,

Anavex Life Sciences Corp. (“Anavex” or the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual

Meeting”) on September 24, 2026. The election of the Company’s board of directors at the Annual Meeting constituted a “change

in control” under the Anavex Life Sciences Corp. 2015 Omnibus Incentive Plan, the Anavex Life Sciences Corp. 2019 Omnibus Incentive

Plan and the Anavex Life Sciences Corp. 2022 Omnibus Incentive Plan (collectively, the “Incentive Plans”) and the Amended

and Restated Employment Agreement, as amended, dated October 4, 2017, between the Company and Sandra Boenisch, the Company’s Principal

Financial Officer (the “PFO Employment Agreement”).

As disclosed in the Company’s Definitive Proxy

Statement on Schedule 14A filed with the Securities and Exchange Commission on August 11, 2026 (the “2026 Proxy Statement”),

under the Incentive Plans and the PFO Employment Agreement, a “change in control” includes when, during any period of 24

consecutive months, the Incumbent Directors (as defined below) cease to constitute a majority of the Company’s board of directors

(hereinafter referred to as a “Board Change CIC”). The term “Incumbent Directors” means individuals who were

members of the Company’s board of directors at the beginning of such period or individuals whose election or nomination for election

to the Company’s board of directors by the Company’s stockholders was approved by a vote of at least a majority of the then

Incumbent Directors, but excluding any individual whose initial election or nomination is in connection with an actual or threatened

proxy contest relating to the election of directors.

The Company’s board of directors, not the Company’s stockholders, initially

appointed Dr. Axel Paeger to the board in February 2026 to fill a vacancy. Mr. Gautam Patel and Dr. Adrian Senderowicz were initially

elected to the Company’s board of directors at the Annual Meeting. As further described below under Item 5.07, the election of

directors at the Annual Meeting was contested. Because the initial election by the Company’s stockholders of Dr. Paeger, Mr. Patel,

and Dr. Senderowicz was in connection with a proxy contest, only Dr. Jiong Ma, Dr. Peter Donhauser and Dr. Claus van der Velden qualify

as Incumbent Directors following the Annual Meeting. Therefore, Incumbent Directors constitute less than a majority of the Company’s

board of directors, and thus triggered the Board Change CIC provision of the Incentive Plans and the PFO Employment Agreement. As a result

of the Board Change CIC, all outstanding and unvested awards granted under the Incentive Plans, including all outstanding and unvested

awards granted to Ms. Boenisch, immediately became fully vested and exercisable in accordance with the terms of the applicable Incentive

Plan and applicable award agreement. See the section entitled “Effects of a Change of Control on Certain Contractual Obligations”

of the 2026 Proxy Statement for additional information.

The amount of voting securities of the Company beneficially owned directly

or indirectly by each of the Company’s current directors as of the date hereto is hereby incorporated by reference from the section

entitled “Security Ownership of Certain Beneficial Owners and Management” of the 2026 Proxy Statement except that all outstanding

and unvested awards held by Dr. Ma, Dr. Donhauser and Dr. van der Velden immediately became fully vested and exercisable as a result of

the Board Change CIC.

To the Company’s knowledge, there are no arrangements or understandings

among members of the Company’s board of directors immediately before and immediately after the Annual Meeting and their respective

associates with respect to the election of directors or other matters. Additionally, there are no arrangements, known to the Company,

including any pledge by any person of securities of the Company, the operation of which may at a subsequent date result in a change in

control of the Company.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On September 24, 2026, the Company held its Annual

Meeting. On September 28, 2026, the independent inspector of the election (the “Inspector”) for the Annual Meeting delivered

its final vote tabulation that certified the voting results for each of the matters that were submitted to a vote at the Annual Meeting.

According to the Inspector’s final tabulation of voting, a total of 54,239,204 shares of the Company’s common stock, par value

$0.001 per share (“Common Stock”) were present or represented by proxy, representing approximately 58.51% of the outstanding

Common Stock as of July 31, 2026, the record date for the Annual Meeting.

At the Annual Meeting, two proposals were submitted

to a vote of the Company’s stockholders. The final voting results, as reported by the Inspector, are as follows:

Proposal No. 1: The election of the Company’s

director nominees, Jiong Ma, Ph.D., Peter Donhauser, D.O., Axel Paeger, M.D., MBA, MBI, Gautam Patel, MBA, Adrian Senderowicz, M.D. and

Claus van der Velden, Ph.D. (the “Company Nominees”), each to hold office until the Company’s next annual meeting of

stockholders or until such director’s successor is elected and qualified. PVG Asset Management Corporation, a beneficial owner of

the Company’s common stock (“PVG”) had nominated six additional director nominees (the “PVG Nominees”) for

election in opposition to the Company Nominees; however, the stockholders did not elect any of the PVG Nominees. The stockholders holding

a majority of the Common Stock having voting power present in person or represented by proxy elected the six Company Nominees by the following

votes:

Name

For

Against

Abstain

Company Nominees

Jiong Ma, Ph.D.

37,010,531

14,315,617

2,879,977

Peter Donhauser, D.O.

44,542,463

7,773,833

1,889,830

Axel Paeger, M.D., MBA, MBI

46,683,049

5,638,004

1,885,074

Gautam Patel, MBA

46,350,328

6,061,752

1,794,048

Adrian Senderowicz, M.D.

47,303,114

5,261,632

1,641,380

Claus van der Velden, Ph.D.

40,411,557

11,506,977

2,287,592

PVG Nominees

Patrick S. Adams

7,694,677

27,662,970

18,848,033

John Boris

7,657,445

27,830,184

18,718,053

Dale Curtis Hogue, Jr.

12,227,373

23,224,072

18,754,237

Jason Kolbert

14,469,637

21,046,035

18,690,010

Rene Mora, M.D., Ph.D.

8,613,380

27,462,036

18,130,266

Ralf von Ziegesar

6,350,445

28,714,810

19,140,276

Proposal No. 2: The stockholders holding a

majority of the Common Stock having voting power present in person or represented by proxy ratified Grant Thornton LLP as the Company’s

independent registered accounting firm for the fiscal year ending September 30, 2026 by the following votes:

For

Against

Abstain

49,432,188

3,068,978

1,738,038

Because of the contested nature of the Annual Meeting, there were no broker

non-votes on any proposal submitted to a vote at the Annual Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange

Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANAVEX LIFE SCIENCES CORP.

/s/ Sandra Boenisch

Name: Sandra Boenisch, CPA, CGA

Title: Principal Financial Officer, Treasurer

Date: September 28, 2026

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.3

Cover

Sep. 24, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 24, 2026

Entity File Number

001-37606

Entity Registrant Name

ANAVEX

LIFE SCIENCES CORP.

Entity Central Index Key

0001314052

Entity Tax Identification Number

98-0608404

Entity Incorporation, State or Country Code

Entity Address, Address Line One

630 5th Avenue

Entity Address, Address Line Two

20th Floor

Entity Address, City or Town

New York

Entity Address, State or Province

Entity Address, Postal Zip Code

10111

City Area Code

844

Local Phone Number

689-3939

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

AVXL

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration